Osilodrostat
Osilodrostat (LCI699) is a potent dual inhibitor of CYP11B1 and CYP11B2, with IC50 values of 2.5 nM and 0.7 nM, respectively. This FDA-approved drug is used for treating Cushing's disease and serves as a key research tool for studying corticosteroid synthesis in both in vitro and in vivo models.
Product Specifications
CAS Number
928134-65-0
Product Name Alternative
Blood pressure, 11β-hydroxylase, aldosterone synthase, CYP11B1, CYP11B2, Cushing syndrome, Osilodrostat, Mineralocorticoid Receptor, inhibit, Inhibitor, LCI 699, LCI699, LCI-699, HAC15 cells, Glucocorticoid Receptor, GlucocorticoidReceptor, primary human adrenocortical cell cultures
Field of Research
Metabolism Research, Pharmacology & Drug Discovery
Purity
98.00% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (8.8 mM) ; DMSO:50 mg/mL (220.03 mM)
Smiles
Fc1cc (ccc1[C@H]1CCc2cncn12) C#N
Molecular Formula
C13H10FN3
Molecular Weight
227.24
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
K3332105 3x 1.0 µg
Col9a3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
Sign In for Pricing
View Details 
